Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLOOD-dose platform trial for dose optimization in haematological diseases
NCT07474961Phase 4Not yet recruiting
- Start
- Mar 2027
- Primary completion
- Dec 2036
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of teclistamab, talquetamab, elranatamab, linvoseltamab, ibrutinib in multiple myeloma (MM), Waldenström macroglobulinemia (WM). Planned start Mar 2027; status: not yet recruiting.
02
Drugs
teclistamabtalquetamabelranatamablinvoseltamabibrutinib
03
Conditions
multiple myeloma (MM)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT07474961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07474961.